Orexigen Therapeutics Inc (OREX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile
- GDPH82505D
- Pages: 40
- May 2017
- Total Views:1143
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
Orexigen Therapeutics Inc (Orexigen) is a biopharmaceutical company which develops and commercializes indications for the treatment of obesity. Its lead product, Contrave (naltrexone HCl / bupropion HCl prolonged release) is FDA approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults. Contrave is also approved in Europe under the brand name Mysimba. The company is also undertaking a range of commercialization activities, to bring Contrave / Mysimba to patients worldwide. The product is also sold in different countries worldwide through Orexigen's partners. The company is also undertaking a range of commercialization activities, to bring Contrave / Mysimba to patients worldwide. Orexigen is headquartered in La Jolla, California, the US.
Orexigen Therapeutics Inc (OREX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
Business Description-A brief description of the company's operations.
Key Employees-A list of the key executives of the company.
Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
Key Competitors-A list of the key competitors of the company.
Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Orexigen Therapeutics Enters into Distribution Agreement with Navamedic 12
Orexigen Therapeutics Enters into Distribution Agreement with Bruno Farmaceutici for Mysimba 12
Orexigen Therapeutics Enters into Distribution Agreement with Consilient Health for Mysimba 13
Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma 13
Orexigen Therapeutics Enters into Distribution Agreement with Valeant for Contrave 14
Orexigen Therapeutics Enters into Distribution Agreement with Laboratorios Farmaceuticos Rovi 15
Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma for Mysimba 15
Orexigen Therapeutics Ireland to Enter into Distribution Agreement with Kwang Dong Pharmaceutical 16
Licensing Agreements 17
Orexigen Therapeutics Enters into Licensing Agreement with University of Bath 17
Equity Offering 17
Orexigen Therapeutics Plans to Raise up to USD20 Million in Public Offering of Shares 17
Orexigen Therapeutics Raises USD60 Million in Private Placement of Shares 18
Orexigen Therapeutics Completes Public Offering Of Common Stock For US$61 Million 19
Orexigen Therapeutics Completes Public Offering Of Units For US$90 Million 20
Debt Offering 22
Orexigen Therapeutics Raises USD165 Million in Private Placement of Notes Due 2020 22
Orexigen Therapeutics Completes Private Placement Of Notes Due 2020 For US$115 Million 23
Orexigen Therapeutics Inc-Key Competitors 25
Key Employees 26
Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
May 11, 2017: Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017 28
Mar 28, 2017: Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016 29
Nov 03, 2016: Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2016 31
Aug 04, 2016: Orexigen Therapeutics Reports Business and Financial Results for the Second Quarter Ended June 30, 2016 33
May 04, 2016: Orexigen Therapeutics Reports Business and Financial Results for the First Quarter Ended March 31, 2016 34
Feb 26, 2016: Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015 35
Corporate Communications 37
May 23, 2016: Orexigen Appoints New Member of Board of Directors and Announces Senior Management Changes 37
Product News 38
11/16/2016: Orexigen Announces Presentation of Data for OREX-1019, a Preclinical Candidate for the Treatment and Management of Drug Addiction 38
Other Significant Developments 39
Jan 11, 2016: Orexigen announces 2016 financial outlook and key priorities 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40
List Of Figure
List of Figures
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
List Of Table
List of Tables
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Orexigen Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Orexigen Therapeutics Enters into Distribution Agreement with Navamedic 12
Orexigen Therapeutics Enters into Distribution Agreement with Bruno Farmaceutici for Mysimba 12
Orexigen Therapeutics Enters into Distribution Agreement with Consilient Health for Mysimba 13
Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma 13
Orexigen Therapeutics Enters into Distribution Agreement with Valeant for Contrave 14
Orexigen Therapeutics Enters into Distribution Agreement with Laboratorios Farmaceuticos Rovi 15
Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma for Mysimba 15
Orexigen Therapeutics Ireland to Enter into Distribution Agreement with Kwang Dong Pharmaceutical 16
Orexigen Therapeutics Enters into Licensing Agreement with University of Bath 17
Orexigen Therapeutics Plans to Raise up to USD20 Million in Public Offering of Shares 17
Orexigen Therapeutics Raises USD60 Million in Private Placement of Shares 18
Orexigen Therapeutics Completes Public Offering Of Common Stock For US$61 Million 19
Orexigen Therapeutics Completes Public Offering Of Units For US$90 Million 20
Orexigen Therapeutics Raises USD165 Million in Private Placement of Notes Due 2020 22
Orexigen Therapeutics Completes Private Placement Of Notes Due 2020 For US$115 Million 23
Orexigen Therapeutics Inc, Key Competitors 25
Orexigen Therapeutics Inc, Key Employees 26
Orexigen Therapeutics Inc, Subsidiaries 27
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Orexigen Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Orexigen Therapeutics Inc (Orexigen) is a biopharmaceutical company which develops and commercializes indications for the treatment of obesity. Its lead product, Contrave (naltrexone HCl / bupropion HCl prolonged release) is FDA approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults. Contrave is also approved in Europe under the brand name Mysimba. The company is also undertaking a range of commercialization activities, to bring Contrave / Mysimba to patients worldwide. The product is also sold in different countries worldwide through Orexigen's partners. The company is also undertaking a range of commercialization activities, to bring Contrave / Mysimba to patients worldwide. Orexigen is headquartered in La Jolla, California, the US.
Orexigen Therapeutics Inc (OREX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
Business Description-A brief description of the company's operations.
Key Employees-A list of the key executives of the company.
Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
Key Competitors-A list of the key competitors of the company.
Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Orexigen Therapeutics Enters into Distribution Agreement with Navamedic 12
Orexigen Therapeutics Enters into Distribution Agreement with Bruno Farmaceutici for Mysimba 12
Orexigen Therapeutics Enters into Distribution Agreement with Consilient Health for Mysimba 13
Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma 13
Orexigen Therapeutics Enters into Distribution Agreement with Valeant for Contrave 14
Orexigen Therapeutics Enters into Distribution Agreement with Laboratorios Farmaceuticos Rovi 15
Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma for Mysimba 15
Orexigen Therapeutics Ireland to Enter into Distribution Agreement with Kwang Dong Pharmaceutical 16
Licensing Agreements 17
Orexigen Therapeutics Enters into Licensing Agreement with University of Bath 17
Equity Offering 17
Orexigen Therapeutics Plans to Raise up to USD20 Million in Public Offering of Shares 17
Orexigen Therapeutics Raises USD60 Million in Private Placement of Shares 18
Orexigen Therapeutics Completes Public Offering Of Common Stock For US$61 Million 19
Orexigen Therapeutics Completes Public Offering Of Units For US$90 Million 20
Debt Offering 22
Orexigen Therapeutics Raises USD165 Million in Private Placement of Notes Due 2020 22
Orexigen Therapeutics Completes Private Placement Of Notes Due 2020 For US$115 Million 23
Orexigen Therapeutics Inc-Key Competitors 25
Key Employees 26
Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
May 11, 2017: Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017 28
Mar 28, 2017: Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016 29
Nov 03, 2016: Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2016 31
Aug 04, 2016: Orexigen Therapeutics Reports Business and Financial Results for the Second Quarter Ended June 30, 2016 33
May 04, 2016: Orexigen Therapeutics Reports Business and Financial Results for the First Quarter Ended March 31, 2016 34
Feb 26, 2016: Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015 35
Corporate Communications 37
May 23, 2016: Orexigen Appoints New Member of Board of Directors and Announces Senior Management Changes 37
Product News 38
11/16/2016: Orexigen Announces Presentation of Data for OREX-1019, a Preclinical Candidate for the Treatment and Management of Drug Addiction 38
Other Significant Developments 39
Jan 11, 2016: Orexigen announces 2016 financial outlook and key priorities 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40
List Of Figure
List of Figures
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
List Of Table
List of Tables
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Orexigen Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Orexigen Therapeutics Enters into Distribution Agreement with Navamedic 12
Orexigen Therapeutics Enters into Distribution Agreement with Bruno Farmaceutici for Mysimba 12
Orexigen Therapeutics Enters into Distribution Agreement with Consilient Health for Mysimba 13
Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma 13
Orexigen Therapeutics Enters into Distribution Agreement with Valeant for Contrave 14
Orexigen Therapeutics Enters into Distribution Agreement with Laboratorios Farmaceuticos Rovi 15
Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma for Mysimba 15
Orexigen Therapeutics Ireland to Enter into Distribution Agreement with Kwang Dong Pharmaceutical 16
Orexigen Therapeutics Enters into Licensing Agreement with University of Bath 17
Orexigen Therapeutics Plans to Raise up to USD20 Million in Public Offering of Shares 17
Orexigen Therapeutics Raises USD60 Million in Private Placement of Shares 18
Orexigen Therapeutics Completes Public Offering Of Common Stock For US$61 Million 19
Orexigen Therapeutics Completes Public Offering Of Units For US$90 Million 20
Orexigen Therapeutics Raises USD165 Million in Private Placement of Notes Due 2020 22
Orexigen Therapeutics Completes Private Placement Of Notes Due 2020 For US$115 Million 23
Orexigen Therapeutics Inc, Key Competitors 25
Orexigen Therapeutics Inc, Key Employees 26
Orexigen Therapeutics Inc, Subsidiaries 27
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Orexigen Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020